- Home
- CCJ vs RPRX Comparison
CCJ vs RPRX Comparison
Compare CCJ & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCJ
- RPRX
- Stock Information
- Founded
- CCJ 1987
- RPRX 1996
- Country
- CCJ Canada
- RPRX United States
- Employees
- CCJ N/A
- RPRX N/A
- Industry
- CCJ Other Metals and Minerals
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- CCJ Basic Materials
- RPRX Health Care
- Exchange
- CCJ Nasdaq
- RPRX Nasdaq
- Market Cap
- CCJ 16.7B
- RPRX 14.2B
- IPO Year
- CCJ N/A
- RPRX 2020
- Fundamental
- Price
- CCJ $50.74
- RPRX $33.15
- Analyst Decision
- CCJ Strong Buy
- RPRX Strong Buy
- Analyst Count
- CCJ 5
- RPRX 4
- Target Price
- CCJ $73.64
- RPRX $42.50
- AVG Volume (30 Days)
- CCJ 3.5M
- RPRX 3.7M
- Earning Date
- CCJ 05-01-2025
- RPRX 05-08-2025
- Dividend Yield
- CCJ 0.22%
- RPRX 2.65%
- EPS Growth
- CCJ 5.30
- RPRX 37.42
- EPS
- CCJ 0.40
- RPRX 2.45
- Revenue
- CCJ $2,290,088,704.00
- RPRX $2,263,576,000.00
- Revenue This Year
- CCJ $7.95
- RPRX $31.30
- Revenue Next Year
- CCJ $11.11
- RPRX $5.82
- P/E Ratio
- CCJ $128.10
- RPRX $13.54
- Revenue Growth
- CCJ 29.88
- RPRX 1.12
- 52 Week Low
- CCJ $35.00
- RPRX $24.05
- 52 Week High
- CCJ $62.55
- RPRX $34.20
- Technical
- Relative Strength Index (RSI)
- CCJ 71.82
- RPRX 57.43
- Support Level
- CCJ $45.42
- RPRX $31.97
- Resistance Level
- CCJ $50.97
- RPRX $34.11
- Average True Range (ATR)
- CCJ 1.65
- RPRX 0.71
- MACD
- CCJ 0.81
- RPRX 0.09
- Stochastic Oscillator
- CCJ 97.92
- RPRX 62.06
About CCJ Cameco Corporation
Cameco Corp is a provider of uranium needed to generate clean, reliable baseload electricity around the globe. one of those uranium producers. It has three reportable segments, Uranium, Fuel Services, and Westinghouse. It derives maximum revenue from the Westinghouse Segment. It has some projects namely; Millennium, Yeelirrie, Kintyre, and Exploration. The company operates in Canada, Kazakhstan, Germany, Australia, and the United States.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.